ScreenerHero

BFRIBiofrontera Inc. Common Stock

NAS · US · Healthcare · Drug Manufacturers - Specialty & Generic · biofrontera-us.com
1.480USD+4.23%Mkt Cap: 21.98M $P/E: —

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL l…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
MERCK Kommanditgesellschaft auf Aktien
$65.19BUSDP/E 23.7
TAK
Takeda Pharmaceutical Co. Ltd.
$58.06BUSD
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$43.98BUSDP/E 20.4
TEVA
Teva Pharmaceutical Industries Limited
$43.51BUSDP/E 62.2
ZOE
Zoetis Inc.
$29.89BUSDP/E 12.7
ZTS
Zoetis Inc.
$32.12BUSDP/E 12.7
UTHR
United Therapeutics Corporation
$22.01BUSDP/E 18.4
VTRS
Viatris, Inc.
$18.75BUSD
SOBI
Swedish Orphan Biovitrum AB
$15.34BUSDP/E 117.3
IPN
Ipsen S.A.
$14.67BUSDP/E 26.4
NBIX
Neurocrine Biosciences, Inc.
$15.51BUSDP/E 22.3
ELAN
Elanco Animal Health Incorporat
$11.98BUSD
RDY
Dr. Reddy's Laboratories Ltd
$10.15BUSDP/E 29.7
KRK
Krka, d. d.
$8.66BUSDP/E 19.0
ALKS
Alkermes plc
$8.11BUSDP/E 127.2
HIMS
Hims & Hers Health, Inc.
$7.88BUSD
LNTH
Lantheus Holdings Inc
$6.53BUSDP/E 23.9
AMRX
Amneal Pharmaceuticals, Inc. Class A
$6.24BUSDP/E 37.3
LQDA
Liquidia Corporation
$6.14BUSDP/E 49.0
KNSA
Kiniksa Pharmaceuticals, Ltd.
$6.08BUSDP/E 79.8

Key Statistics

Company
Market Cap21.98M $
Enterprise Value24.82M $
Revenue (TTM)46.17M $
Gross Profit30.74M $
Net Income (TTM)-10.54M $
Revenue/Share3.923 USD
Last Price1.480 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees84
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)3.44
PEG—
EV/EBITDA-4.16
EV/Revenue0.54
P/S0.48
P/B3.53
EPS (TTM)-0.45
EPS (Forward)0.43
52W Range
0.555096% of range1.520
52W High1.520 USD
52W Low0.5550 USD
Profitability
Gross Margin73.71%
Oper. Margin-4.37%
EBITDA Margin-12.93%
Profit Margin-25.26%
ROE-100.53%
ROA-36.89%
Growth
Revenue Growth32.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF-13.36M $
CapEx (TTM)2.00K $
FCF Margin-16.84%
FCF Yield-35.38%
Net Debt2.84M $
Net Debt/EBITDA-0.48
Balance Sheet
Debt/Equity0.59
Current Ratio1.18
Quick Ratio0.97
Book Value/Sh0.4190 USD
Cash/Share0.3140 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:20
Split DateJul 5, 2023
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)6.000 USD
Upside (mean)+305.4%
Target Range3.000 USD – 9.000 USD
$3.000+305.4% to mean$9.000
# Analysts2
Ownership
Shares Out.14.85M
Float10.50M
Insiders11.99%
Institutions20.72%
Short Interest
Short Ratio0.1d
Short % Float0.50%
Short % Out.0.48%
Shares Short61.08K
Short (prev mo.)27.89K
Technical
SMA 501.119 (+32.3%)
SMA 2000.9523 (+55.4%)
Beta—
S&P 52W Chg18.16%
Avg Vol (30d)415.00K
Avg Vol (10d)639.42K
Technical Indicators
RSI (14)77.0
MACD0.0826
MACD Signal0.0622
MACD Hist.+0.0204
BB Upper1.442 USD
BB Middle1.228 USD
BB Lower1.015 USD
BB Width34.77%
ATR (14)0.0884 USD
Vol Ratio (20d)0.94x